Ziftomenib with venetoclax and azacitidine for relapsed/refractory NPM1-mutated acute myeloid leukemia.

BloodOct 1, 2026
Clinical ResearchHematologyOncology (Medical)

Eunice S Wang, Harry Erba, Amer M Zeidan et al.

✦ AI-curated · Sources linked

In 30 seconds

The KOMET-007 phase 1 trial evaluated the combination of ziftomenib with venetoclax and azacitidine in adults with relapsed/refractory NPM1-mutated acute myeloid leukemia (AML). Among 67 patients, the composite complete remission (CRc) rate was 46% with ziftomenib 600 mg, and 67% achieved measurable residual disease negativity. The study highlights the tolerability and efficacy of this combination therapy.

Key findings

  • Composite complete remission (CRc) rate was 46% (22/48) with ziftomenib 600 mg.
  • In venetoclax-naïve patients, CRc rate was 70% (16/23).
  • Median duration of response was 8.6 months.
  • 67% (12/18) achieved central measurable residual disease negativity (<0.01% threshold).

Why it matters

This study provides evidence for a promising treatment combination in a challenging patient population with relapsed/refractory NPM1-mutated AML, potentially improving outcomes and offering new therapeutic options.

Source

PubMed · PMID 42227701

Published in Blood. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Hematology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.